In literature so far, 10 methylation markers have been described for disease load monitoring and/or detection of minimal residual disease in liquid biopsies of CRC patients, namely EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC [19], SEPT9, SHOX2 [23], BCAT1, IKFZ1 [21, 22], and B4GALT1 [20]. This evidence concerns the gene BCAT1 and colorectal carcinoma.